BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21884660)

  • 1. [5-aminosalicylic acid for induction of remission or clinical response in Crohn's disease--a survey of a Cochrane review].
    Bjerrum JT; Munck LK; Nielsen OH
    Ugeskr Laeger; 2011 Aug; 173(35):2110-3. PubMed ID: 21884660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Wang Y; MacDonald JK; Hanauer S
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
    Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
    Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.
    Ford AC; Kane SV; Khan KJ; Achkar JP; Talley NJ; Marshall JK; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):617-29. PubMed ID: 21407190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
    Feagan BG
    Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385
    [No Abstract]   [Full Text] [Related]  

  • 8. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
    Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2003 Aug; 18(3):263-77. PubMed ID: 12895211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis.
    Ford AC; Khan KJ; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Mar; 106(3):413-20. PubMed ID: 20717106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease.
    Akobeng AK; Gardener E
    Cochrane Database Syst Rev; 2005 Jan; (1):CD003715. PubMed ID: 15674913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesalamine derivatives in the treatment of Crohn's disease.
    Harrell LE; Hanauer SB
    Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: maintenance treatment of Crohn's disease.
    Biancone L; Tosti C; Fina D; Fantini M; De Nigris F; Geremia A; Pallone F
    Aliment Pharmacol Ther; 2003 Jun; 17 Suppl 2():31-7. PubMed ID: 12786610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical effects of 5-aminosalicylic acid preparations in Crohn disease].
    Fleig WE
    Med Klin (Munich); 1999 Feb; 94 Suppl 1():22-5. PubMed ID: 10194944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
    Moum B
    Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of 5-aminosalicylates for the maintenance of remission in Crohn's disease.
    Akobeng AK
    Am J Gastroenterol; 2011 Oct; 106(10):1857; author reply 1857-8. PubMed ID: 21979212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.